Contribution of von Willebrand Factor to Thrombus Formation on Neointima of Rabbit Stenotic Iliac Artery Under High Blood-Flow Velocity
- 1 June 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 23 (6) , 1105-1110
- https://doi.org/10.1161/01.atv.0000077206.35631.b2
Abstract
Objective— It has become clear that von Willebrand factor (vWF) plays important roles in platelet adhesion and aggregation under high blood-flow velocity conditions observed in stenotic atherosclerotic arteries. However, its roles in thrombus formation in vivo on diseased arteries have not been fully understood. We examined the contribution of vWF to thrombus formation and subsequent intimal growth by using a repeated balloon-injury model in rabbits. Methods and Results— Rabbit iliac arteries 4 weeks after a first balloon injury showed 37% luminal stenosis by neointimal growth, and blood velocity increased by 2.1 times compared with that of uninjured arteries. The second balloon injury induced fibrin-rich thrombus formation on the injured neointima. Intravenous administration of a monoclonal antibody against vWF (AJW200, 1.0 mg/kg body weight) remarkably prevented botrocetin-induced platelet aggregation ex vivo for 2 days; moreover, thrombus formation, cell proliferation, and subsequent neointimal growth were significantly reduced at 30 minutes, 5 days, and 4 weeks, respectively, after the second balloon injury. Conclusions— These results indicate that vWF plays a potent role in fibrin-rich thrombus formation on the neointima under high blood-flow velocity conditions. Inhibition of plasma vWF activity might be effective for the reduction of thrombus formation and/or subsequent neointimal development after coronary interventions.Keywords
This publication has 24 references indexed in Scilit:
- The restenosis paradigm revisited: An alternative proposal for cellular mechanismsPublished by Elsevier ,2010
- Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trialThe Lancet, 2001
- Acute coronary syndromes: The degree and morphology of coronary stenosesJournal of the American College of Cardiology, 2000
- Networking in the Hemostatic SystemJournal of Biological Chemistry, 1997
- Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factorBritish Journal of Pharmacology, 1997
- Localization and activity of tissue factor in human aortic atherosclerotic lesionsAtherosclerosis, 1997
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993
- Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque.Proceedings of the National Academy of Sciences, 1989
- Thrombosis and the Development of Atherosclerosis: Rokitansky RevisitedSeminars in Thrombosis and Hemostasis, 1988
- von Willebrand protein facilitates platelet incorporation in polymerizing fibrin.Journal of Clinical Investigation, 1986